anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This investigation will be the first of its kind to conduct a clinical trial of an industrial hemp-derived product in individuals with anxiety. Despite the recent interest in medical cannabis and cannabinoid-based products, the availability of hemp-derived products in all 50 states, and anecdotal evidence suggesting that hemp-derived products may have a profound anxiolytic effect, no studies have conducted a clinical trial of a hemp-derived product in individuals who suffer from anxiety.

This investigation is composed of two phases. Phase 1 is comprised of a six-week open-label clinical trial of the custom formulated hemp-derived high-CBD solution in individuals with anxiety (n=12). Participants will be pre-screened by phone in order to evaluate their eligibility for the study. If approved, participants will come to the hospital for a baseline/screening visit, and will complete a structured clinical interview, clinical and quality of life questionnaires, and cognitive assessments. Enrolled participants will be given study product to use for the duration of the study; participants will be instructed to self-administer the solution under the tongue twice daily for six weeks. Throughout the treatment period, participants will complete short in-person or phone visits on a weekly basis, where they will complete questionnaires about their mood and quality of life. Participants will also return to the hospital for a final visit after six weeks of treatment to complete additional questionnaires and cognitive assessments.

Phase 2 of the study is a double-blind clinical trial of this solution in patients with anxiety (n=40). This double-blind trial will begin after the open-label trial has been completed. In the same manner as the open-label trial, participants will be pre-screened by phone, and approved participants will come to the hospital for a baseline/screening visit to complete a structured clinical interview, questionnaires, and cognitive assessments. Eligible participants will also have the option to complete an hour-long MRI scan at the baseline and final visits. Enrolled participants will receive either CBD solution or placebo solution to self-administer throughout the six week treatment period, as described above. Participants will complete in-person visits and phone check-ins during the treatment period to complete questionnaires about their mood and quality of life. Participants in this phase of the study will also return for a final visit after six weeks of treatment to complete additional questionnaires, cognitive assessments, and an optional MRI scan. Note: Phase 2 was planned but study termination occurred prior to commencement.
PCT No. PCT/FR85/00264 Sec. 371 Date Jul. 31, 1986 Sec. 102(e) Date Jul. 31, 1986 PCT Filed Sep. 26, 1985 PCT Pub. No. WO86/02098 PCT Pub. Date Apr. 10, 1986.The invention concerns hybridomes producing anti-Leishmania monoclonal antibodies which are characterized by their capacity to inhibit the infection of sarcomatous cells by the promastigote forms of one or more species of Leishmania, when the sarcomatous cells are placed in contact with the said promastigote forms pre-incubated with these monoclonal antibodies under conditions which, in the absence of the said monoclonal antibodies, would lead to an elevated parasitemia in the said cells. These monoclonal antibodies and the proteins of the parasites that they recognize may be used in the operations of leishmanioses detections.
Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
Totally American Society of Anesthesiologists (ASA) I-II, 18-60 ages, 583 patients who had had oral and maxillofacial operations for 30 minutes and over with TIVA and IA methods between 1st Jan, 2016 and 1st Jan, 2017. The ones who had insufficient data in their files and who were conscious / superficial sedation patients were excluded from the study. The patients were allocated to two groups as TIVA and IA. The total intravenous anesthesia group was named "Group TIVA" , and the volatile anesthesia group was named "Group IA".

All the patients were opened vascular access after being taken into the operation room and were given anesthesia induction with 1 µg/kg fentanyl, 2 mg/kg propofol and 0,8 mg/kg rocuronium. The patients in Group IA were given 1-2% volume sevoflurane in 50% oxygen and 50% nitrous oxide during maintenance of anesthesia, while the patients in group TIVA were applied 4-10 mg/kg/h propofol and 0.05-0.1 µg/kg fentanyl IV infusion with 50% oxygen and 50% air. While being woken up, each patient was given 0.3 mg/kg tenoxicam for analgesia and 0.2 mg/kg metoclopramide for nausea-vomiting prophylaxis in a routine way. Each patient was taken into recovery room after extubation and pulse rate, non-invasive blood pressure (NIBP) and oxygen saturation monitorization were done. Postoperative complication and vital finding tracks of each patient were done as usual and were recorded.
BACKGROUND: The ubiquitin-proteasome system regulates protein degradation and the development of pulmonary arterial hypertension (PAH), but knowledge about the role of deubiquitinating enzymes in this process is limited. UCHL1 (ubiquitin carboxyl-terminal hydrolase 1), a deubiquitinase, has been shown to reduce AKT1 (AKT serine/threonine kinase 1) degradation, resulting in higher levels. Given that AKT1 is pathological in pulmonary hypertension, we hypothesized that UCHL1 deficiency attenuates PAH development by means of reductions in AKT1.
METHODS: Tissues from animal pulmonary hypertension models as well as human pulmonary artery endothelial cells from patients with PAH exhibited increased vascular UCHL1 staining and protein expression. Exposure to LDN57444, a UCHL1-specific inhibitor, reduced human pulmonary artery endothelial cell and smooth muscle cell proliferation. Across 3 preclinical PAH models, LDN57444-exposed animals, Uchl1 knockout rats (Uchl1-/-), and conditional Uchl1 knockout mice (Tie2Cre-Uchl1fl/fl) demonstrated reduced right ventricular hypertrophy, right ventricular systolic pressures, and obliterative vascular remodeling. Lungs and pulmonary artery endothelial cells isolated from Uchl1-/- animals exhibited reduced total and activated Akt with increased ubiquitinated Akt levels. UCHL1-silenced human pulmonary artery endothelial cells displayed reduced lysine(K)63-linked and increased K48-linked AKT1 levels.
RESULTS: Supporting experimental data, we found that rs9321, a variant in a GC-enriched region of the UCHL1 gene, is associated with reduced methylation (n=5133), increased UCHL1 gene expression in lungs (n=815), and reduced cardiac index in patients (n=796). In addition, Gadd45α (an established demethylating gene) knockout mice (Gadd45α-/-) exhibited reduced lung vascular UCHL1 and AKT1 expression along with attenuated hypoxic pulmonary hypertension.
CONCLUSIONS: Our findings suggest that UCHL1 deficiency results in PAH attenuation by means of reduced AKT1, highlighting a novel therapeutic pathway in PAH.
PURPOSE:To obtain a bone matrix synthesis promoter contained a heat-shock protein, capable of specifically promoting synthesis of procollagen in osteoblast and useful for therapy of osteoporosis, etc. CONSTITUTION:This bone matrix synthesis promoter contains a heat-shock protein (HSP), e.g. an HSP such as HSP 47 having a molecular weight of <=50 K dalton. The preferable dosage form of this promoter is injection and preparation of this injection is carried out, e.g. by dissolving HSP 47 and mannitol in distilled water, sterilizing it according to the conventional method and subsequently freeze-drying it. This promoter is administrated in an amount of 0.01 to 3000mg/day per an adult, especially 0.1 to 500mg/day per an adult on HSP base.
Subjects in Group 1 will have leads placed in their lower back. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
Retention is necessary to be done after orthodontic treatment. It aids to prevent the tendency for relapse of teeth toward their pretreatment position. Fixed or removable retention appliances can reduce the risk of relapse, but to date there is still limited evidence on treatment protocols, wearing time and duration. However, long-term retention with bonded lingual retainers is commonly recommended and often considered the gold standard (method of first choice) in orthodontic retention. Regardless of the expected benefits concerning tooth stabilization, aesthetic appearance and independency from the patient's compliance, there have been increasing numbers of reports on undesirable changes in tooth position in the presence of retainers. Since "active" lingual retainers are able to exert forces to teeth, they have been suspected of causing torque changes of adjacent incisors ("X-effect"). Therefore, several authors recommend to insert removable and fixed in both arches for maximum relapse prevention.
Collective cancer invasion exhibits a hierarchical structure characterized by leader-follower organization. Dynamic gene expression analysis of invading cells using nanobiosensors within 3D microenvironments provides a valuable means to explore the regulation of leader cells during collective cancer invasion. Nonetheless, the analysis of time-lapse, multimodal images that capture the intricacies of complex invading structures and gene expression profiles in 3D tumor spheroids poses a significant technological challenge. Here, we present a computer vision-based workflow that streamlines the identification of protrusions and detached clusters from 3D tumor spheroids. This methodology not only discerns invading multicellular structures and quantifies their physical properties, but also captures gene expression patterns associated with these invasive mechanisms using an intracellular nanobiosensor. Consequently, it empowers a systematic exploration of the genotypic and phenotypic heterogeneities inherent in cancer invasion. To illustrate the effectiveness of this approach, we applied it to the analysis of a long noncoding RNA, MALAT1, in tumor spheroids derived from patients with muscle-invasive bladder cancer. Our investigation delved into the heterogeneity of cancer invasion and its relationship to MALAT1 expression. Overall, this workflow represents a valuable tool for gaining insights into the complexities of cancer invasion.
Aussie current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
BACKGROUND: Fentanyl is an opioid analgesic frequently used in the emergency department (ED) and is usually administered without knowing the QTC values of the patients or being monitored. However, the effect of fentanyl on QTC, prolongation or shortening, has not been elucidated. This study aimed to determine the effect of fentanyl on QTC.
METHODS: This is a prospective observational study in the ED of a tertiary hospital on patients who received intravenous fentanyl for procedures other than intubation. ECG was performed before and at 1, 5, 15, 30, and 60 min after the initiation of fentanyl administration, and QTC value was calculated. Primary outcomes were QTC prolongation, defined as an increase in the QTC to ≥ 500 ms or any increase in QTC by ≥ 60 ms.
RESULTS: The study included 109 patients. Of these, 60 patients were male, and the median age was 40. Compared with the baseline QTC value, statistically significant prolongation was detected at the 5th, 15th, 30th, and 60th minutes, with the maximum prolongation at 30 min, and the median was 13.08 ms. Most patients with QTC prolongation were female and over 40 years of age. Clinically, none of these patients developed malignant arrhythmias during the 60-minute monitored observation period.
CONCLUSION: Fentanyl prolonged the QTC value statistically significantly. Although no patient developed malignant arrhythmia clinically, our results suggest that this QTC-prolonging effect should be considered when using fentanyl in patients at risk of torsades.
Embodiments of the present disclosure can provide systems, methods, and computer-readable medium for tracking the heartrate of a user using different techniques associated with different contexts. For example, motion of a user wearing a wearable device can be tracked using at least first sensors of the one or more sensors. The physical state of the user can also be tracked using at least second sensors of the one or more sensors. In some cases it can be determines whether an application of the wearable device has been launched. Additionally, an activity category of the user can be determined based at least in part on the motion of the user, the physical state of the user, and/or whether the application has been launched. Heartrate data of the user can be collected, and the heartrate data can be categorized based at least in part on the determined category.
PURPOSE: A composition containing Glycyrrhizae radix extract and Albizia julibrissin DURAZZ. extract is provided to reduce sleep latency and to enhance sleep duration. CONSTITUTION: A composition for improving sleeping contains Glycyrrhizae radix extract or Albizia julibrissin DURAZZ. extract as an active ingredient. The Glycyrrhizae radix extract is obtained by extracting Glycyrrhizae radix using 26-32% ethanol at 38-44°C for 10-14 hours. The Albizia julibrissin DURAZZ. extract is obtained by extracting Albizia julibrissin DURAZZ. with 52-62% ethanol at 18-60°C for 22-60 hours. The mixture ratio of Glycyrrhizae radix extract or Albizia julibrissin DURAZZ. extract is 2.5-3.5:0.5-1.5. A functional food for improving sleeping contains the Glycyrrhizae radix extract or Albizia julibrissin DURAZZ. extract as an active ingredient.
Managing advanced colon cancer is challenging, requiring targeted therapies. This study presents a novel nanoconjugate system, HA-CMD@ETP-MLT-NCs, designed to deliver etoposide (ETP) specifically to colon cancer cells. The system consists of Hyaluronic Acid (HA)-Functionalized Carboxymethyl Dextran (CMD) coated with Melatonin (MLT). The nanoconjugates showed good stability, with a zeta potential of -29.90 mV and a particle size of 199.1 nm. They achieved an 80.3 % yield and a high drug entrapment efficiency of 93.4 %. In vitro release studies demonstrated pH-dependent drug release, with 73.4 % released at pH 5.5 (tumour-like environment) and 42.6 % at pH 7.4 (normal tissue) over 24 h. The nanoconjugates improved cellular uptake, induced apoptosis, and reduced reactive oxygen species (ROS) in HCT116 colon cancer cells. Flow cytometry showed a significant decrease in ROS levels, and lipid peroxidation inhibition increased to 56.67 %. These findings suggest that HA-CMD@ETP-MLT-NCs enhance etoposide delivery and reduce side effects. Further in vivo studies and clinical trials are needed to confirm its therapeutic potential.
These clinical studies are designed to examine the acute effects of intravenous nicotine on anterior pituitary (ACTH, LH) and adrenal hormones (DHEA and cortisol). We also plan to study norepinephrine (NE) and epinephrine (E), because nicotine stimulates rapid release of NE and E in preclinical and clinical studies. The studies will examine the acute effects of intravenous nicotine on the gonadal steroid hormones and the reciprocal feedback regulation by LH. The temporal covariance of hormonal changes with serum nicotine levels and nicotine-induced changes in subjective states and cardiovascular measures will be measured. The covariance between nicotine-induced changes in endocrine, subjective and cardiovascular effects and the temporal concordance with increases in serum nicotine and cotinine levels will be determined. Gender and menstrual cycle phase influences on the effects of nicotine on HPA and HPG hormones and subjective effects will be assessed.
Control training refers to similarly structured gait training as with REAL, with the only exception of using soft robotic exosuits. Control training is performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. Control training includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
PURPOSE: Acute gastrointestinal bleeding is a common emergency. Tranexamic acid (TXA) reduces clot breakdown by inhibiting the action of plasmin and has been shown to reduce the need for blood transfusion in trauma, surgical procedures, and upper gastrointestinal bleeding. This study examined the efficiency of intravenous TXA in patients with acute lower gastrointestinal bleeding.
METHODS: Eighty-one patients aged >18 years with lower GI hemorrhage, presenting as active rectal bleeding and anemia (hemoglobin lower than 11 g/dL or a decrease of 2 gr/dl from the patient's base level), were enrolled in this single center, double blind prospective research. Patients were randomly assigned to receive intravenous TXA or placebo from admission until colonoscopy took place. The need for transfusion of packed red blood cells (PRBC) and number of units was recorded and compared between the two groups.
RESULTS: Eighty-one patients were randomized in this study, thirty-nine in the TXA arm, and forty-two in the placebo arm. Patient characteristics did not differ between the groups. Forty-three out of the 81 patients received blood transfusion; twenty-two were on the placebo arm and twenty-one on the TXA arm (p = 0.89). Twenty-nine patients required 2 or more units, 14 in the TXA arm and 15 in the placebo arm (p = 0.98).
CONCLUSIONS: Intravenous TXA has no significant effect on blood requirement in patients with lower GI bleeding. There was no difference in the consumption of PRBC units among the patients in the placebo and TXA groups. It seems that tranexamic acid has no significant effect on transfusion of PRBC units in lower GI bleeding.
PROBLEM TO BE SOLVED: To extremely quickly obtain a tocol derivative-betaine complex by adding a small amount of a specific agent on the reaction of a tocol derivative with a betaine. SOLUTION: This method for producing a tocol derivative-betaine complex powder comprises mixing a tocol derivative with a betaine and a reaction accelerator. Therein, the crystals of the betaine are eliminated instantaneously or in an extremely short time to give the substantially white powder. For example, a method comprising mixing the betaine with the reaction accelerator and subsequently adding the tocol derivative to the mixture gives the powdery complex especially excellent in flowability. The reaction accelerator includes citric acid, acetic acid, lactic acid, glycerol, propylene glycerol, polyglycerol and cetyl lactate. The tocol derivative is preferably d-α-tocopherol, d,l-α- tocopherol, etc. The tocol derivative and the betaine are used in a weight ratio of 10:(10-0.5).
A method, system and computer program product for facilitating compliance with a dietary restriction. Preparation criteria for the dietary restriction are compared to preparation notes for a food item. A dietary solution is provided that is compatible with the dietary restriction, e.g. to approve or disallow a food item, or to provide a preparation plan for preparing the food item to make it compatible with the dietary restriction. An identified ingredient or dietary restriction may be expanded be searching for related ingredients or characteristics. A customized menu may be prepared. The method may be implemented via a distributed computing network, and databases may be established to store data relating to ingredients, related ingredients, food preparation procedures, etc. in relation to dietary restrictions and/or food items.
<P>PROBLEM TO BE SOLVED: To provide a medicinal composition having an enhanced dissolution stability of bazedoxifene.  <P>SOLUTION: The medicinal composition includes bazedoxifene, and antioxidants such as vitamin E, vitamin E TPGS, propyl gallate, citric acid, and BHA/BHT and is substantially free of ascorbic acid. A method of production of the composition is provided. Methods for increasing dissolution stability of bazedoxifene and biological application capability of preparations containing antioxidants are described. A method for reducing interaction among at least either bazedoxifene or hydroxymethyl cellulose, ascorbic acid and at least one kind of one or more than one decomposition products of ascorbic acid is presented.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PURPOSE: The adopted treatment for chronic elbow PLRI is lateral ulnar collateral ligament reconstruction. However, the most frequently reported complication after primary reconstruction is recurrent instability - up to 25 %. It was thus hypothesized that enhancing the secondary stabilizers will provide successful results with a lower rate of recurrent instability in comparison to techniques with primary reconstruction only. This study aimed to demonstrate a novel surgical technique involving secondary stabilizers.
METHODS: In this retrospective study of 29 cases with chronic PLRI the mean duration of symptoms was 39.6 ± 4.9 months. The mean age was 47.9 years with mainly male patients. The surgeries were performed by one senior surgeon at a single institution. The Mayo Elbow Performance Score (MEPS) and the Disabilities of the Arm, Shoulder and Hand questionnaire (DASH) were recorded.
RESULTS: The mean follow-up was 36.8 ± 7.7 months. The MEPS score improved significantly from 59.8 ± 13.1 to 84.7 ± 7.6 (p < 0.001). 23/29 patients (79.2 %) had converted to good and excellent results (MEPS >75 points). The DASH score improved from 40.8 ± 4.6 to 20.9 ± 7.2 (p < 0.001). The total complication rate was 10.3 % (N = 3). No recurrent instability was recorded in comparison to 12.2 % for primary reconstruction only, as reported in the literature (p < 0.05).
CONCLUSION: Enhancing the secondary stabilizers by utilizing an adjacently located autograft provided good and excellent results with no recurrent instability. This novel surgical procedure is easy to reproduce and provides a safe and reliable alternative in cases of chronic PLRI when compared to techniques with primary reconstruction only.